Investment Rating - The report recommends a "buy" rating for the cosmetics and medical beauty sectors, highlighting a favorable outlook for 2025 due to improved consumer expectations and policy support [4][6]. Core Insights - The report emphasizes that the cosmetics sector will focus on three key elements: domestic brands, segmentation, and cost-effectiveness, with a projected steady growth in demand for 2025 [4][6]. - The medical beauty industry is expected to benefit from improved income expectations, with domestic companies poised to become major competitors in the light medical beauty segment [4][6]. - E-commerce is identified as a growth area, with new consumption models and brands emerging to drive development [4][6]. Summary by Sections 1. Industry Performance Review - The beauty and personal care sector has not achieved excess returns in 2025 due to trading disruptions, but is expected to rebound with policy support [7][8]. - The SW beauty index has seen a growth of 0.6% since the beginning of 2025, underperforming compared to the broader A-share index [8][10]. 2. Cosmetics Sector - The report forecasts a recovery in the cosmetics demand in 2025, with a focus on high cost-performance brands benefiting from consumer preferences [15][18]. - Domestic brands are gaining market share, with significant growth in the skincare market, where domestic brands now occupy four out of the top ten positions [18][19]. - The report highlights the success of domestic brands in e-commerce platforms, particularly during promotional events, indicating a strong competitive position against international brands [21][22]. 3. Medical Beauty Sector - The medical beauty market is transitioning from a blue ocean to a red ocean, with domestic companies expanding their product lines and research pipelines [4][6]. - Key recommendations include focusing on companies with strong product pipelines and high profitability, such as Ai Meike [4][6]. 4. E-commerce Sector - The report suggests that the e-commerce sector will continue to thrive with the rise of new consumption models and brands, particularly benefiting from the growth of domestic brands [4][6]. 5. Key Company Recommendations - The report recommends several companies based on their brand matrix and growth potential, including Shangmei Co., Pulaile, and others in the cosmetics sector [4][6]. - In the medical beauty sector, Ai Meike is highlighted as a key player, with a focus on companies with strong product offerings and research capabilities [4][6].

2025 年 3 月 10 日 招银国际环球市场 | 睿智投资 | 行业研究 中国医药 预期药品集采政策优化，期待"创新药目录"落地 MSCI 中国医疗指数 2025 年初至今累计上涨 12.9%，跑输 MSCI 中国指数 7.6%。 受益于国内药品价格政策优化、国内宏观环境改善以及海外降息预期，医药行业有 望在 2025 年继续迎来估值修复。丙类医保目录年内即将落地，创新药将获得更好 的支付环境。医疗设备招标加速复苏，将推动国产医疗设备企业盈利复苏。 估值表 | | | | 市值 | 目标价 | 上行/ | P/E (x) | | P/B (x) | | ROE (%) | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 公司名称 | 股份代码 | 评级 | (百万美元) | | | | (LC) 下行空间 FY25E FY26E FY25E FY26E FY25E FY26E | | | | | | 百济神州 | ONC US | 买入 | 27,422.2 | 359.47 | 40% | 209 ...

行业研究 2025.03.10 商 贸 零 售 行 业 周 报 天猫"3.8"首日可复美/毛戈平/绽家排名显著进阶，孩子王与头部算力算法企业合作布局 AI+ 方 正 证 券 研 究 所 证 券 研 究 报 告 分析师 | 刘章明 | 登记编号：S1220523050001 | | --- | --- | | 周昕 | 登记编号：S1220524100007 | | 陈佳妮 | 登记编号：S1220520080002 | | 谷寒婷 | 登记编号：S1220524030001 | | 廖捷 | | --- | | 联系人 | 行业评级 : 推 荐 | 行 | 业 | 信 | 息 | | | --- | --- | --- | --- | --- | | 上市公司总家数 | | | | 144 | | 总股本(亿股) | | | | 2,923.62 | | 销售收入(亿元) | | | | 21,639.47 | | 利润总额(亿元) | | | | 1,570.81 | | 行业平均 PE | | | | 24.83 | | 平均股价(元) | | | | 15.49 | 行 业 相 对 指 数 表 现 -2 ...

Investment Rating - The report maintains a "Strong Outperform" rating for the social services sector [6]. Core Insights - The government emphasizes boosting consumption and investment to expand domestic demand, aiming to make it a primary driver of economic growth [1][4]. - The report highlights the importance of optimizing the consumption environment and enhancing service supply in sectors like health, elderly care, and tourism [4]. - The report notes a significant increase in domestic tourism, with Heilongjiang province expecting to receive 135.08 million visitors in the 2024-2025 winter season, a year-on-year growth of 18.5% [5]. Summary by Sections Market Performance - The consumer services sector saw a weekly increase of 3.27%, outperforming the Shanghai Composite Index by 1.72 percentage points [2]. - The commercial trade sector had a modest increase of 0.48%, underperforming the Shanghai Composite Index by 1.08 percentage points [2]. Sector Performance - The outbound tourism sector led with a 9.04% increase, while hotels, restaurants, and scenic spots showed varied performance [3]. - The e-commerce and services sector also performed well, with a 3.90% increase, indicating strong consumer engagement [3]. Policy and Regulatory Developments - The government plans to implement special actions to boost consumption, including measures to enhance consumer capacity and improve the consumption environment [4]. - The report mentions the allocation of 300 billion yuan in special government bonds to support the replacement of old consumer goods [4]. Investment Recommendations - The report suggests monitoring the duty-free sector closely, especially with the expected decline in sales in early 2025, while also noting the potential benefits from policy optimizations [37]. - The hotel sector is expected to stabilize in 2025, with a focus on improving operational efficiency and managing supply pressures [39]. - The restaurant sector faces challenges but may see improvements in efficiency and market dynamics as competition evolves [42].

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the market by more than 5% over the next six months [33]. Core Insights - The high-end beauty market in China has experienced rapid growth from 2017 to 2021 but is currently influenced by the overall macro environment and consumer sentiment. Domestic leading brands have strengthened their competitiveness in product formulation, design, marketing, and brand operation, leveraging e-commerce channels to quickly gather consumer demand and respond to market changes. Brands like Proya and Juzhibio are expected to capture market share as they cater to the demand for quality products at lower price points, pushing out Japanese and Korean cosmetics [2][9]. - The solid-state battery technology is emerging as a significant advancement in battery performance, with potential applications in various sectors, including low-altitude flying vehicles and humanoid robots. The technology is expected to overcome the limitations of traditional liquid lithium batteries, with domestic companies actively developing solid-state battery production capabilities [4][16]. Summary by Sections Beauty Industry - The domestic beauty market has shown a significant increase in sales during promotional events, with GMV exceeding 11.3 billion yuan during the 3.8 promotional period, marking a 71.86% increase year-on-year. Skincare and makeup categories also saw substantial growth [7][8]. - Leading domestic brands like Proya, Juzhibio, and others have maintained strong positions in the market, with Proya consistently ranking first in beauty sales on platforms like Tmall [8][9]. Solid-State Battery Industry - Solid-state batteries are positioned to break through existing performance bottlenecks, with advancements in materials and technology expected to enhance energy density and safety. The industry is seeing a shift towards solid-state technology, with significant investments and developments from leading companies like CATL and Penghui Energy [4][15][16]. - The demand for solid-state batteries is driven by their superior energy density and safety features, making them suitable for applications in electric vehicles and new technology sectors. The supply chain is evolving, with companies focusing on innovative materials and production processes to meet future demands [15][16].

Investment Rating - The investment rating for the beauty care industry is "Recommended" (maintained) [2][22]. Core Insights - The beauty care industry is experiencing significant growth driven by technological innovation and personalized services, with AI and big data being utilized to provide tailored solutions for consumers [4][22]. - The report emphasizes the importance of new material technologies and the rise of personalized services as mainstream trends in the medical beauty sector [22]. Summary by Sections Recent Market Performance - From March 3 to March 7, 2025, the Shenwan Beauty Care Index increased by 2.94%, with notable stock performances from companies like Kedi-B and Juzhi Biotechnology [7][8]. Industry News - The report highlights the successful launch of the "China Quality Flagship Store" by Hangzhou Meilai, which aims to redefine high-quality medical beauty standards through a comprehensive service system [12]. - Juzhi Biotechnology's patented recombinant human type IV collagen has been approved, marking a breakthrough in the medical beauty industry [4]. Key Company Announcements - Huadong Medicine's optical radiofrequency therapy device V30 has received acceptance from the National Medical Products Administration (NMPA), showcasing its multifunctional capabilities [10]. - Betaini's brand "Beforteen" has integrated AI technology for acne diagnosis, enhancing its product offerings [11]. Investment Recommendations - The report suggests focusing on companies with strong growth potential, including: 1. Marubi Biotechnology, known for its comprehensive brand matrix and product range [22]. 2. Juzhi Biotechnology, which is expected to grow rapidly due to the rise of recombinant collagen and domestic beauty trends [22]. 3. Betaini, which combines high cost-performance with strong product innovation [22]. 4. Aimeike and Longzi Co., which are expected to drive growth through flagship products and extensive product pipelines [22]. 5. Huadong Medicine, which shows strong potential in innovative drug development and medical beauty product pipelines [22].

Investment Rating - The report suggests a positive outlook for the beauty and medical aesthetics industry, highlighting strong performances from specific companies during the promotional period [4]. Core Insights - The report emphasizes the resilience of domestic brands in the beauty sector, with a stable market share of 25% for domestic brands on Tmall compared to the previous year [2]. - Notable performances include Proya, which maintained its top position, and Juzibio, which improved its ranking significantly on Tmall [2]. - On Douyin, the beauty category's GMV reached over 11.3 billion yuan, marking a 72% increase from the previous year, with skincare and makeup categories showing substantial growth [3]. Summary by Sections Tmall Platform - The top four brands maintained their positions, with domestic brands holding a 25% market share, consistent with the previous year [2]. - Proya ranked first, while Juzibio's Kefu Mei moved up five places to eighth, driven by strong sales of its collagen products [2]. - Maogeping entered the top 20 for the first time, with significant sales from its caviar mask and cushion foundation [2]. Douyin Platform - The beauty category's GMV exceeded 11.3 billion yuan, a 72% increase year-on-year [3]. - Skincare products generated over 8.4 billion yuan, with a 65% increase from the previous year, while the makeup category saw a 106% growth, reaching over 2.4 billion yuan [3]. - Maogeping's makeup sales reached between 50 million to 75 million yuan, significantly improving its market position [3]. Overall Market Performance - Companies such as Juzibio, Maogeping, and Proya showed exceptional performance during the promotional period, indicating strong market dynamics [4].

Investment Rating - The report recommends several companies in the retail sector, including leading brands in various categories such as children's retail, beauty, medical aesthetics, and jewelry [5][6]. Core Insights - The report highlights the ongoing transformation of the company, focusing on quality retail and optimizing store operations to better match consumer demand in Changsha, where the consumer base is young and economically active [4][5][30]. - The company has undergone significant restructuring, reducing the number of its supermarkets from 343 to 96 and its department stores from 43 to 37 between 2021 and 2023, aiming to streamline operations and focus on core areas [3][12][17]. - The introduction of a new management team from a successful competitor has led to impressive sales growth in restructured stores, with some locations reporting sales increases of over 300% during peak periods [5][51]. Summary by Sections 1. Background and Progress of Restructuring - The company has faced continuous operational pressure since 2021, leading to a strategic overhaul that includes closing underperforming stores and focusing on core business areas [3][11][17]. - The restructuring process has been supported by a new management team, which is implementing comprehensive changes across various operational aspects [18][19]. 2. Consumer Structure and Characteristics in Changsha - Changsha's GDP has shown steady growth, with a projected increase of over 5.5% in 2025, indicating a robust economic environment for retail [30][31]. - The demographic profile of Changsha is notably young, with nearly 50% of the population aged 18-24, which drives demand for differentiated products and services [4][39]. 3. Performance of Reformed Stores - The report details the successful transformation of several stores, with significant increases in sales and customer traffic post-restructuring [5][51][58]. - Specific stores have reported remarkable sales figures, with daily sales reaching as high as 240.22 million yuan during peak periods [51]. 4. Key Company Financial Forecasts and Valuations - The report provides earnings per share (EPS) forecasts and price-to-earnings (PE) ratios for various recommended companies, indicating strong growth potential in the retail sector [6].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, indicating that the industry is expected to outperform the benchmark index over the next 12 months [33]. Core Insights - The pharmaceutical sector is experiencing a recovery, with significant growth in sub-sectors such as internet healthcare, biotechnology, and medical devices, which saw increases of 36%, 34%, and 24% respectively in February 2025 [3][6]. - The report highlights the government's encouragement of innovative drug development, including discussions on expanding payment channels for innovative drugs and the potential establishment of a category for innovative drugs in the insurance framework [4][24]. - The medical device market is showing signs of recovery, with the domestic medical imaging equipment market growing over 47% year-on-year in January 2025, and an increase in the number of CT devices awarded contracts by 4.2% compared to the previous year [4][30]. Market Review - In February 2025, the Hang Seng Composite Industry Index rose by 12.8%, while the Hang Seng Healthcare Index increased by 16.3%, outperforming the market by 3.5 percentage points [3][6]. - The A-share market saw the Shanghai and Shenzhen 300 Index decline by 3% in January, with the pharmaceutical and biotechnology index dropping by 3.8%, but rebounding in February with a 5.1% increase [14]. - The report notes that all 13 sub-sectors in the pharmaceutical industry experienced declines in January, but several sub-sectors, including hospitals and medical devices, showed significant gains in February [14]. Industry Data Update - The report indicates that the basic medical insurance revenue for January 2025 reached 314.3 billion yuan, a year-on-year increase of 10.4%, with expenditures growing by 8.5% [17]. - The commercial health insurance sector is also expanding, with original premium income reaching 977.3 billion yuan in 2024, reflecting an 8.2% year-on-year growth [20]. - Medical device exports, particularly for ECG recorders, ultrasound diagnostic devices, and CT machines, have accelerated in both quantity and value since the second half of 2024 [21]. Industry News Summary - The National Healthcare Security Administration held a meeting to support innovative drug development, engaging with major pharmaceutical companies to discuss strategies for enhancing the market for innovative drugs [23][24]. - A draft opinion on improving the drug pricing mechanism has circulated, proposing measures to support innovative drug development and enhance drug accessibility [28]. - The report mentions ongoing efforts to regulate prices in the healthcare sector, including a comprehensive governance initiative for central venous catheter pricing, which has led to significant price reductions for related medical services [29][30].

Summary of Conference Call Notes Industry Overview - The focus is on the consumer market for 2025, with expectations of gradual stabilization despite current weak demand indicators [2][6][20] - The consumer market is anticipated to reach a new equilibrium due to supply-side adjustments during the economic downturn [2][3] Key Insights and Arguments - **Market Performance**: The consumer market has not yet shown a clear upward trend, but signs of stabilization are emerging, particularly in sectors like fast food (e.g., KFC) and condiments (e.g., Haitian) [2][3] - **Consumer Confidence**: Although retail sales and consumer confidence indices remain weak, they are beginning to stabilize, with high-income groups showing improved income expectations [4][6] - **Investment Opportunities**: There is a low actual allocation in consumer stocks despite a pessimistic market outlook, indicating potential investment opportunities as funds may shift focus [5][20] - **Policy Impact**: Government policies aimed at stimulating consumption, particularly for low- and middle-income groups, are expected to play a significant role in market recovery [9][10][17] - **Investment Strategy**: A two-tier investment strategy is recommended: focusing on data resilience in the left phase and waiting for economic recovery signals in the right phase [10][20] Important but Overlooked Content - **Sector Recommendations**: Emphasis on investing in strong brands with stable operations, particularly in the food and beverage sector, as well as essential consumer goods like dairy products [12][16] - **Long-term Trends**: Future consumer trends include a focus on value-for-money products, emotional value, and the application of new technologies in consumer goods [19][20] - **Specific Stock Recommendations**: Companies like Meituan, Alibaba, and emerging brands in the new consumption space (e.g., Maogeping, Honey Snow Ice City) are highlighted for their potential in the current market environment [13][18][20] - **White Liquor Sector**: While the white liquor sector is expected to recover more slowly, it remains a critical area for investment due to its market significance [15][20] Conclusion - The consumer market is poised for gradual recovery, with specific sectors and companies presenting viable investment opportunities. Monitoring key economic indicators and government policies will be crucial for navigating the investment landscape in 2025 [6][11][17]